Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Improving Preparatory Materials for the Pediatric Infectious Diseases Initial Certifying Exam: A Targeted Needs Assessment
Sattler, Matthew M , Ristagno, Elizabeth H. , Boguniewicz, Juri , Fatemi, Yasaman , Jamal, Hassan H. , Vidal, Diego A Cruz , Boguniewicz, Juri , Jamal, Hassan, Parzen-Johnson, Simon

Journal of the Pediatric Infectious Diseases Society | May 25, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1093/jpids/piaf048 | PMID 40413637 Get It

Abstract We conducted a national survey of current pediatric infectious diseases (PID) fellows and PID fellowship graduates from the past 10 years to assess satisfaction with existing PID initial certifying exam preparatory materials. Satisfaction with existing resources was low. The most desired new resource was additional board-style questions.
Study protocol for an internahaational prospective non-randomised trial evaluating the long-term outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement for aortic-valve stenosis in patients at risk to severe valve obst
Nappi, Francesco , Bourgois, Camille, Schoell, Thibaut, Fiore, Antonio, Spadaccio, Cristiano , Nappi, Francesco , Nenna, Antonio , Salsano, Antonio , El‐Dean, Zein , Fiore, Antonio

BMJ Open | May 24, 2025 | Volume: 15 | Issue: 5 | Pages: e101417

10.1136/bmjopen-2025-101417 | PMID 40413055 Get It

Background Aortic valve stenosis (AVS) represents the most prevalent primary valvular lesion necessitating surgical intervention or transcatheter intervention in Europe and North America. Its prevalence is increasing at a rapid rate as a consequence of the ageing population. A variety of mechanical interventions are available to determine the management of AVS; however, there is currently a paucity of robust data with which to perform a comparative analysis of the efficacy of surgical aortic valve replacement (SAVR) and that of conventional stented xenograft bioprostheses (BP) or sutureless aortic valves (SAV) and transcatheter aortic valve implantation (TAVI). The present study aims to compare the effectiveness and clinical outcomes of SAVR using BP or SAV technique and TAVI in patients with severe AVS. Methods and analysis A collaboration between three cardiac surgery centres across two European countries has resulted in the conception of the Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement trial. This prospective non-randomised trial is designed to evaluate the long-term outcomes of TAVI in comparison to SAVR for AVS in patients at risk of severe valve obstruction. The registry will enrol successive patients who have undergone mechanical intervention for AVS between January 2015 and December 2025. Investigators will assess the difference between replacement procedures for both the standard surgical approach and the transcatheter procedure. The principal clinical outcome under consideration will be the composite degree of all-cause mortality, ischaemic stroke or rehospitalisation at 10 years. The present study will also have a number of secondary endpoints, including all-cause mortality, followed by functional status, hospitalisation, neurocognition, physiological measures (echocardiographic assessment), adverse events and reoperation. Ethics and dissemination It is hypothesised that the nature of the trials will serve to minimise bias related to institutional volume and surgical experience. Each participating centre is required to have an aortic valve programme that enables proper follow-up and management of any late aortic events following replacement surgery for the AVS. The data collected will provide valuable insight into the comparative effectiveness of various surgical approaches, both standardised and advanced, in aortic valve surgery and TAVI. This comprehensive analysis will contribute significantly to the development of robust international guidelines. Trial registration number Clinical Trial Gov.Com. ID: NCT05261204 IRB. ID: 2022011057
PlacEntal Acute atherosis RefLecting Subclinical systemic atherosclerosis in women up to 20 years after pre-eclampsia (PEARLS): research protocol for a cohort study
Jansen, Gwyneth , Alers, Robert‐Jan , Janssen, Emma BNJ, Jorissen, Laura M , Morina-Shijaku, Eri, Severens‐Rijvers, C., Hof, Arnoud W.J. van ’t , Drongelen, J. van , Stevens, D.U. , Gordijn, Sanne J. , Cornette, Jérôme , Mihl, Casper , Kietelaer, Bas L J H, Ghossein‐Doha, Chahinda , Spaanderman, Marc E. A. , Ganzevoort, Wessel , Kietelaer, Bas, Jansen, G , Janssen, Emma BNJ, Scholten, Ralph R. , Al‐Nasiry, Salwan

BMJ Open | May 24, 2025 | Volume: 15 | Issue: 5 | Pages: e100542

10.1136/bmjopen-2025-100542 | PMID 40413047 Get It

Introduction Despite being a leading cause of female morbidity and mortality, female-specific cardiovascular disease (CVD) is understudied, underdiagnosed and undertreated. Pregnancy complications involving the placenta, including pre-eclampsia, pregnancy-induced hypertension and foetal growth restriction, are thought to reflect global maternal vascular derangements that indicate a twofold to eightfold increased risk of future CVD. This calls for a better understanding of female cardiovascular pathophysiology to allow development of targeted screening and prevention strategies. Acute atherosis is a placental vascular lesion, which histologically resembles systemic atherosclerosis. The PlacEntal Acute atherosis RefLecting Subclinical atherosclerosis study investigates the association between placental acute atherosis lesions and subclinical systemic atherosclerosis up to 20 years postpartum. This study will improve our understanding of the relationship between pregnancy complications and CVD to identify potential prevention targets and treatments. In addition, it could determine whether the placenta can improve identification of young women at high risk of CVD. These women could benefit from risk-reducing interventions. Methods and analysis This longitudinal prospective cohort study will include women who are either currently pregnant or from a historical cohort. Both groups will have placental histopathology and a single postpartum CVD assessment. The CVD assessment will include medical history taking, blood tests, electrocardiography and echocardiography. Additionally, coronary CT angiography focusing on the presence of atherosclerotic plaques and calcium score will be carried out. The currently pregnant women will either have a pre-eclamptic pregnancy (pre-eclamptic group) or an uncomplicated normotensive pregnancy (uncomplicated group), and their placenta will be collected prospectively. The single CVD assessment will be carried out 6–36 months postpartum. Women from the historical cohort had a pre-eclamptic pregnancy 10–20 years ago. Placental tissue is available for reanalysis. The single CVD assessment will take place immediately and corresponds with 10–20 years postpartum. Exclusion criteria are contraindications to diagnostic assessment necessities: iodinated contrast, beta-blockers or glyceryl trinitrate. Women with uncomplicated pregnancies will be excluded if they have a pre-existing auto-immune condition, chronic hypertension or diabetes mellitus. In the pre-eclamptic group, there are no additional exclusion criteria. Ethics and dissemination Ethical approval was granted by the Medical Ethics Committee in Maastricht University Medical Centre+ (NL52556.068.15/METC152019). Participants will give written informed consent. Results will be shared in peer-reviewed journals and conference presentations. Trial registration number NCT05500989 ; ClinicalTrials.gov Identifier.
Reply to: Comment on: Guidelines for use and safety of corticosteroid injections in joints and musculoskeletal soft tissue
Benzon, Honorio T. , Souza, Dmitri , Nagpal, Ameet , Hunt, Christine , Provenzano, David , FitzGerald, John , Provenzano, David Anthony , Benzon, Honorio T , Hunt, Christine , Nagpal, Ameet S , FitzGerald, John D

Regional Anesthesia & Pain Medicine | May 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-106815

10.1136/rapm-2025-106815 | PMID 40412820 Get It

Optimizing measures of insulin-regulated lipolysis in humans
Song, Yilin , Lytle, Kelli A. , Jensen, Michael D.

American Journal of Physiology-Endocrinology and Metabolism | May 24, 2025 | Volume: 329 | Issue: 1 | Pages: E59-E66

10.1152/ajpendo.00078.2025 | PMID 40411805 Get It

Accurate measures of insulin regulation of adipose tissue lipolysis (free fatty acid release rates) in humans can be accomplished using a two-step, hyperinsulinemic clamp experimental design, but careful scrutiny of the data is needed. The FFA palmitate IC 50 measure is reproducible in weight-stable adults and responds to treatment interventions in a quantitative manner.
Vascular protection by young circulating extracellular vesicles ameliorates aging-related pulmonary fibrosis
Gianì, Fiorenza , Roos, B., Link, Patrick A. , Somasundram, Bharath , Dresler, Sara R. , Sciacca, Enrico, Javeed, Naureen , Ligresti, Giovanni , Tschumperlin, Daniel J. , Tschumperlin, Daniel J , Caporarello, Nunzia , Link, Patrick A , Vancheri, Carlo , Caporarello, Nunzia

American Journal of Physiology-Cell Physiology | May 24, 2025 | Volume: 329 | Issue: 1 | Pages: C159-C169

10.1152/ajpcell.00022.2025 | PMID 40411768 Get It

This study demonstrates that circulating extracellular vesicles (cEVs) isolated from young mice reverse the transcriptional alterations of the aged mouse pulmonary vasculature, leading to a more youthful endothelial transcriptional phenotype. As a result of this vascular phenotype, aged mice are protected from bleomycin-induced pulmonary fibrosis. These findings highlight the therapeutic potential of targeting vascular aging to alleviate pulmonary fibrosis.
IL-17A potentiates malignant T-cell viability via electron transport chain complex I in cutaneous T-cell lymphoma
Attrish, Diksha , Dhamija, Bhavuk , Mukherjee, Ditipriya , Sawant, Vinanti , Marathe, Soumitra , Saul, Dominik , Basu, Moumita , Banik, Ankit , Sharma, Neha , Shet, Tanuja, Jain, Hasmukh , Sharma, Priyanka , Purwar, Rahul , Saul, Dominik , Kosinsky, Robyn Laura

No container title available | May 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.21.655309 Get It

Abstract Cutaneous T-cell lymphoma (CTCL) is a rare malignancy of skin-resident T cells characterized by an aberrant cytokine profile, notably elevated Interleukin-17A (IL-17A) levels. However, the functional importance of IL-17A dysregulation in the CTCL pathogenesis remains poorly understood. Our analysis revealed increased IL-17A receptor (IL-17RA) expression in CTCL patient samples, supporting the importance of IL-17A signaling in CTCL progression. Proteomic and metabolomic profiling of IL-17A-treated malignant T cells revealed mitochondrial electron transport chain (ETC) complex I as a key downstream target of IL-17A signaling. Furthermore, we confirmed the elevated expression of ETC complex I in CTCL patient samples compared to healthy control T cells, hence highlighting the clinical relevance of the IL-17A signaling-ETC complex 1 axis. Altogether, our data unveil the function of IL-17A signaling in the metabolic axis in CTCL progression, which could be useful for developing advanced therapeutic strategies. Significance statement: We uncover an IL-17A-induced electron transport chain (ETC) complex I pro-tumorigenic circuit and provide proof of concept evidence that ETC complex I can be targeted to combat the challenges posed by Cutaneous T-cell Lymphoma aggressiveness.
Practice patterns and experiences of pediatric rehabilitation medicine physicians in cancer rehabilitation
Tsao, Elaine , Levin, Jared, Gober, Joslyn , Chaviano, Kelli , Tsetlina, Vera , Javaid, Simra , Tsao, Elaine Ya-Wei , Lynch, Mary Elizabeth, Lynch, Mary Elizabeth

PM&R | May 24, 2025 | Volume: 17 | Issue: 11 | Pages: 1334-1342

10.1002/pmrj.13395 | PMID 40411370 Get It

Abstract Background Pediatric cancer rehabilitation is a growing field, and pediatric rehabilitation medicine physicians play an important role in the care continuum for children and adolescents with cancer. However, the current practice patterns and experiences of pediatric physiatrists in cancer rehabilitation are not well known. Objective To evaluate the status of pediatric cancer rehabilitation care by board‐certified pediatric physiatrists in the United States, including their practice pattern, experience, and comfort level in cancer‐related conditions. Design An online 37‐question Research Electronic Data Capture survey was developed by members of a pediatric cancer rehabilitation committee of a national physiatry organization. Descriptive data analysis was performed. Setting Survey invitations were sent via email to potential participants and posted on social media sites, including an online physiatry community forum and a pediatric physiatrist private group. Patients (or Participants) Targeted participants were board‐certified pediatric physiatrists who treat pediatric patients with cancer diagnoses. Interventions Not applicable. Main Outcome Measure(s) Survey questions pertained to respondents' practice setting and patient population, type of cancer rehabilitation provided, presence of a cancer rehabilitation program at their institution, and their learning experience in pediatric cancer rehabilitation. Results A total of 107 board‐certified pediatric physiatrists completed the survey, representing 57 institutions in the United States, the majority of which were academic centers ( n = 95; 88.8%). Ninety‐seven (90.7%) reported their practice consisted of >75% pediatric patients, and 95 (88.8%) indicated <25% pediatric patients in the practice have cancer diagnoses. Forty respondents representing 19 institutions (33.3%) reported an established cancer rehabilitation program at their institution, though of these, 23 (57.5%) indicated that more improvement to their program was needed. Sixty‐three respondents (58.9%) gained experience in cancer rehabilitation from fellowship, 51 (47.7%) from residency, and 47 (43.9%) from mentorship; majority ( n = 102; 95.3%) also learned from self‐study or on the job. Participants' comfort level on cancer‐related conditions varied. Conclusions This survey, aimed at board‐certified pediatric physiatrists who practice pediatric cancer rehabilitation, highlights the variety in training experiences and practice exposure among respondents. Concomitant with this was a variance in reported comfort levels in treating the different cancer‐related diagnoses. This raises for discussion what training opportunities might be strengthened as the subspeciality continues to grow.
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
Petersen, Ronald C. , Graf, Ana, Atkins, Alexandra S. , Murphy, Jennifer, Miller, David S. , Reyderman, Larisa, Siemers, Eric , Smith, Janice , Carrillo, María C. , Weber, Christopher J., Bryś, Mirosław , Murphy, Jennifer

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 24, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/trc2.70069 | PMID 40417267 Get It

Abstract The Alzheimer's disease (AD) scientific field continues to make significant advances in early detection and treatments, which importantly rest on advances in our fundamental understanding of AD pathobiology and its contribution to cognitive decline. Clinical readouts of monoclonal antibodies against various forms of the amyloid beta (Aβ) protein indicate that the impact of these treatments may extend beyond reduction in amyloid plaques. The Alzheimer's Association Research Roundtable meeting held on May 17 and 18, 2022, reviewed our understanding to date of the impact of treatments targeting various species of Aβ; its impact on other related pathophysiology including tau; and ultimately, its effects on neurodegeneration and clinical decline, driven by the latest available data. Participants discussed the current evidence for a causal relationship among amyloid accumulation, tau alteration, and cognitive decline; the effect of anti‐amyloid therapies on clinical and biomarker endpoints; and how we can accelerate the pathway to therapeutic approval and what should guide us for the near future. Highlights The Alzheimer's Association Research Roundtable convened leaders from industry and academia, as well as patients, clinicians, and government and regulatory agency scientists to discuss the topic “Current Understanding of AD Pathophysiology & Impact of Amyloid‐beta Targeted Treatments on Biomarkers and Clinical Endpoints.” The totality of scientific evidence (clinical trials, animal data, modeling, and observational studies) on the relationship between amyloid beta (Aβ), amyloid, tau, and cognitive impairment is helping our understanding of the downstream effects and overall importance of lowering amyloid plaque load. Based on data from multiple phase 2 and 3 clinical trials of anti‐amyloid monoclonal antibodies, there is strong evidence to support that a sufficiently large reduction in amyloid plaque load to near‐normal levels is associated with positive changes in tau biomarkers and clinical endpoints. Reduction of Aβ plaque, measured easily by plasma amyloid biomarkers, is reasonably likely to predict benefit in clinical outcome measures.
Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease
Hassenstab, Jason , Sung, Yun Ju, Daniels, Alisha , Xiong, Chengjie , Perrin, Richard J. , Day, Gregory S. , Supnet, Charlene , Berman, Sarah , Chhatwal, Jasmeer P. , Huey, Edward D. , Ryan, Natalie S. , Laske, Christoph , Xiong, Chengjie , Roh, Jee Hoon , Lopera, Francisco , team, For DIAN study, McDade, Eric M , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Roh, Jee Hoon , Supnet-Bell, Charlene , Berman, Sarah , Liu, Haiyan , Bui, Quoc Van Phu , Gordon, Brian A. , Benzinger, Tammie L.S. , Timsina, Jigyasha , Sung, Yun Ju, Karch, Celeste M. , Renton, Alan , Morris, John C. , Ibanez, Laura , Llibre‐Guerra, Jorge J. , Xu, Xiong, Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Jucker, Mathias , Vöglein, Jonathan , Lopera, Francisco Javier , Bateman, Randall J. , Cruchaga, Carlos , McDade, Eric , team, For DIAN study

Alzheimer's & Dementia | May 24, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70243 | PMID 40411302 Get It

AbstractINTRODUCTIONThis study investigated the role of the ubiquitin–proteasome system (UPS) in dominantly inherited Alzheimer's disease (DIAD) by examining cerebrospinal fluid (CSF) levels of UPS proteins.METHODThe SOMAscan assay was used to detect changes in UPS proteins in mutation carriers (MCs) relative to disease progression; imaging and CSF biomarkers of amyloid, tau, and neurodegeneration measures; and Clinical Dementia Rating scale.RESULTSSubtle increases in specific ubiquitin enzymes were detected in MCs up to two decades before symptom onset, with more pronounced elevations in UPS‐activating enzymes near symptom onset. Significant correlations were found between UPS proteins and Alzheimer's disease (AD) biomarkers, especially between autophagy markers and late‐stage tau biomarkers, microglia, and axonal degeneration.DISCUSSIONThe rise in UPS proteins alongside tau‐related markers suggests UPS involvement in tau neurofibrillary tangles. Elevated CSF UPS proteins in DIAD MCs may serve as indicators of disease progression, and may support the UPS as a therapeutic target in AD.Highlights This study investigates the ubiquitin‐proteasome system (UPS) in Dominantly Inherited Alzheimer's Disease (DIAD), highlighting early molecular changes linked to disease progression. Using SOMAscan proteomics, we identified significant UPS protein alterations in cerebrospinal fluid of mutation carriers, notably up to 20 years before clinical symptom onset. Correlations between UPS protein levels and Alzheimer's biomarkers, particularly tau and neurodegeneration markers, suggest a strong association between UPS dysregulation and tau pathology in DIAD. Dynamic UPS changes align with A/T biological staging: UPS proteins were shown to increase across Aβ/tau (A/T) groups, with largest increases in the A+/T+ group, reinforcing their role in late‐stage tau pathology and disease progression. These findings underscore the potential of UPS proteins as early biomarkers for Alzheimer's disease progression and as novel therapeutic targets, especially in tau‐pathology‐driven neurodegeneration. This work contributes to understanding AD pathogenesis, by emphasizing the importance of protein quality control systems and by offering avenues for future biomarker discovery and therapeutic development in Alzheimer's disease.